Industry News

Sun Pharmaceutical Industries Ltd announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U.S.1 CEQUA is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL™) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

US based, Myaln reported that they will invest one billion USD in the next 5 to 6 years on capex in India by understanding importance of the India's position in world pharma supply-chain, and pitched for the government incentivising research and development activities. Mylan had been investing close to about 400 to 450 mn USD towards Capex every year and half of it in India.

Roche presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatment of people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy. In the study, Tecentriq plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) compared with platinum-based chemotherapy alone (median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82, 95% CI: 0.70-0.96; p=0.007).

Glenmark Pharmaceuticals Ltd., a research-led, integrated global pharmaceutical company, today announced that it has received approval from the Ministry of Healthcare, Russia to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film-coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Montlezir is expected to be available in the Russian market in Q3 FY 2019-20.

Caption: L-R: Mr. Vivek Seigell, Principal Director, PHD Chamber, Mr. BhargavKotadia, Managing Director, Sahajanand Medical Technologies, Shri. D. V. SadanandaGowda,Hon’ble Minister of Chemicals & Fertilizers, Govt. of India, Dr. D. K. Aggarwal, Sr. Vice President, PHD Chamber, Dr. T. S. Kler, Chairman (Hospitals), Health Committee, PHD Chamber, Prof. Bejon Misra, Chairman, Public Health Committee, PHD Chamber and Dr Jitendar Sharma, Industry Expert- Medical Technologies

The World Health Organization (WHO) congratulates the Government of Kenya for launching the world’s first malaria vaccine  in Homa Bay County, western Kenya.

Indoco Remedies announced that the Inspection Action Group (IAG) of the United Kingdom has confirmed that the GMP status for its Goa Plant I has been fully re-instated by UK regulator, The Medicines and Healthcare Products Regulatory Agency of the United Kingdom (UK-MHRA). This is an outcome of the full GMP inspection conducted by the MHRAfrom May 21 - 23, 2019.

Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China. 

Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China.

Boehringer Ingelheim and Lupin Limited (Lupin) joined in for a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers.